Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study Evaluating ARQ-255
December 05, 2022 08:00 ET
|
Arcutis Biotherapeutics, Inc.
ARQ-255 is a topical janus kinase (JAK) inhibitor therapy specifically designed as a potential treatment for alopecia areataProprietary Deep Dermal Drug Delivery (4D) formulation designed to deliver...
ROSEN, A LEADING LAW FIRM, Encourages AbbVie Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – ABBV
May 04, 2022 16:53 ET
|
The Rosen Law Firm PA
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE: ABBV) between April 30, 2021 and August...
ROSEN, A TOP RANKED FIRM, Encourages AbbVie Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ABBV
April 30, 2022 11:48 ET
|
The Rosen Law Firm PA
NEW YORK, April 30, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE: ABBV) between April 30, 2021 and...
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages AbbVie Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – ABBV
April 09, 2022 15:06 ET
|
The Rosen Law Firm PA
NEW YORK, April 09, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...